drugset / Trial / NCT00639327
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Phase 2/3
Completed
300 enrolled
Japan Clinical Cancer Research Organization
Taiho Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is compare overall survival of the test arm (CPT-11/S-1 combination) to the control arm (CPT-11 alone) in the subjects with S-1 refractory advanced gastric cancer.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-04
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 60 mg/m2 | Oral |